Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.21
OMCL's Cash-to-Debt is ranked lower than
91% of the 1921 Companies
in the Global Health Information Services industry.

( Industry Median: 10.13 vs. OMCL: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
OMCL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: No Debt Max: No Debt
Current: 0.21
Equity-to-Asset 0.46
OMCL's Equity-to-Asset is ranked lower than
69% of the 1830 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. OMCL: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
OMCL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.57  Med: 0.7 Max: 0.78
Current: 0.46
-0.57
0.78
Interest Coverage 3.91
OMCL's Interest Coverage is ranked lower than
89% of the 1467 Companies
in the Global Health Information Services industry.

( Industry Median: 173.79 vs. OMCL: 3.91 )
Ranked among companies with meaningful Interest Coverage only.
OMCL' s Interest Coverage Range Over the Past 10 Years
Min: 0.77  Med: 275.5 Max: 2381.5
Current: 3.91
0.77
2381.5
Piotroski F-Score: 4
Altman Z-Score: 2.86
Beneish M-Score: -2.54
WACC vs ROIC
7.22%
1.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 0.94
OMCL's Operating Margin % is ranked lower than
64% of the 1862 Companies
in the Global Health Information Services industry.

( Industry Median: 4.84 vs. OMCL: 0.94 )
Ranked among companies with meaningful Operating Margin % only.
OMCL' s Operating Margin % Range Over the Past 10 Years
Min: 0.31  Med: 7.72 Max: 11.25
Current: 0.94
0.31
11.25
Net Margin % 0.09
OMCL's Net Margin % is ranked lower than
63% of the 1863 Companies
in the Global Health Information Services industry.

( Industry Median: 3.19 vs. OMCL: 0.09 )
Ranked among companies with meaningful Net Margin % only.
OMCL' s Net Margin % Range Over the Past 10 Years
Min: 0.09  Med: 5.1 Max: 20.32
Current: 0.09
0.09
20.32
ROE % 0.14
OMCL's ROE % is ranked lower than
65% of the 1803 Companies
in the Global Health Information Services industry.

( Industry Median: 6.16 vs. OMCL: 0.14 )
Ranked among companies with meaningful ROE % only.
OMCL' s ROE % Range Over the Past 10 Years
Min: 0.14  Med: 5.35 Max: 25.13
Current: 0.14
0.14
25.13
ROA % 0.07
OMCL's ROA % is ranked lower than
61% of the 1927 Companies
in the Global Health Information Services industry.

( Industry Median: 2.92 vs. OMCL: 0.07 )
Ranked among companies with meaningful ROA % only.
OMCL' s ROA % Range Over the Past 10 Years
Min: 0.08  Med: 4.01 Max: 17.93
Current: 0.07
0.08
17.93
ROC (Joel Greenblatt) % 5.42
OMCL's ROC (Joel Greenblatt) % is ranked lower than
62% of the 1883 Companies
in the Global Health Information Services industry.

( Industry Median: 23.13 vs. OMCL: 5.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OMCL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.43  Med: 45.83 Max: 91.06
Current: 5.42
2.43
91.06
3-Year Revenue Growth Rate 20.90
OMCL's 3-Year Revenue Growth Rate is ranked higher than
85% of the 1454 Companies
in the Global Health Information Services industry.

( Industry Median: 5.30 vs. OMCL: 20.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OMCL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: 10.6 Max: 20.9
Current: 20.9
-53.3
20.9
3-Year EBITDA Growth Rate 5.50
OMCL's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 1210 Companies
in the Global Health Information Services industry.

( Industry Median: 8.40 vs. OMCL: 5.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OMCL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -13.6  Med: 18 Max: 121.1
Current: 5.5
-13.6
121.1
3-Year EPS without NRI Growth Rate -69.00
OMCL's 3-Year EPS without NRI Growth Rate is ranked lower than
97% of the 1098 Companies
in the Global Health Information Services industry.

( Industry Median: 7.70 vs. OMCL: -69.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OMCL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.7  Med: 7.5 Max: 260.9
Current: -69
-69.7
260.9
GuruFocus has detected 7 Warning Signs with Omnicell Inc $OMCL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OMCL's 10-Y Financials

Financials (Next Earnings Date: 2017-05-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OMCL Guru Trades in Q1 2016

Paul Tudor Jones 17,445 sh (+76.21%)
Jim Simons Sold Out
Ken Fisher 531,000 sh (-4.15%)
» More
Q2 2016

OMCL Guru Trades in Q2 2016

Ken Fisher 536,152 sh (+0.97%)
Paul Tudor Jones Sold Out
» More
Q3 2016

OMCL Guru Trades in Q3 2016

Ken Fisher 517,464 sh (-3.49%)
» More
Q4 2016

OMCL Guru Trades in Q4 2016

Steven Cohen 33,900 sh (New)
Jim Simons 23,243 sh (New)
Ken Fisher 507,114 sh (-2.00%)
» More
» Details

Insider Trades

Latest Guru Trades with OMCL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Health Information Services    NAICS: 621999    SIC: 8099
Compare:NYSE:EVH, NAS:PINC, NYSE:TDOC, NAS:INOV, NAS:WBMD, NAS:QSII, NAS:HSTM, NAS:NH, NAS:HQY, OTCPK:PMCUF, NAS:CPSI, NYSE:EVDY, NAS:RCM, NAS:TRHC, OTCPK:SNBP, OTCPK:COGZF, OTCPK:CNAB, OTCPK:TLLT, NAS:COOL, OTCPK:APTOF » details
Traded in other countries:OC9.Germany,
Headquarter Location:USA
Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing.

Omnicell provides automation and business analytics software for healthcare providers. The firm operates in two segments: automation and analytics and medication adherence. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. This segment contributes the majority of revenue. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.

Ratios

vs
industry
vs
history
PE Ratio 2005.00
OMCL's PE Ratio is ranked lower than
100% of the 1245 Companies
in the Global Health Information Services industry.

( Industry Median: 25.80 vs. OMCL: 2005.00 )
Ranked among companies with meaningful PE Ratio only.
OMCL' s PE Ratio Range Over the Past 10 Years
Min: 8.9  Med: 42.29 Max: 2032.5
Current: 2005
8.9
2032.5
Forward PE Ratio 29.94
OMCL's Forward PE Ratio is ranked lower than
77% of the 535 Companies
in the Global Health Information Services industry.

( Industry Median: 20.20 vs. OMCL: 29.94 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 2005.00
OMCL's PE Ratio without NRI is ranked lower than
100% of the 1229 Companies
in the Global Health Information Services industry.

( Industry Median: 26.21 vs. OMCL: 2005.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
OMCL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.9  Med: 42.29 Max: 2032.5
Current: 2005
8.9
2032.5
Price-to-Owner-Earnings 93.04
OMCL's Price-to-Owner-Earnings is ranked lower than
88% of the 724 Companies
in the Global Health Information Services industry.

( Industry Median: 22.94 vs. OMCL: 93.04 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
OMCL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.72  Med: 33.96 Max: 3988.33
Current: 93.04
7.72
3988.33
PB Ratio 3.39
OMCL's PB Ratio is ranked lower than
56% of the 1789 Companies
in the Global Health Information Services industry.

( Industry Median: 2.97 vs. OMCL: 3.39 )
Ranked among companies with meaningful PB Ratio only.
OMCL' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.36 Max: 6.93
Current: 3.39
0.96
6.93
PS Ratio 2.11
OMCL's PS Ratio is ranked higher than
53% of the 1780 Companies
in the Global Health Information Services industry.

( Industry Median: 2.34 vs. OMCL: 2.11 )
Ranked among companies with meaningful PS Ratio only.
OMCL' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.15 Max: 4.68
Current: 2.11
0.95
4.68
Price-to-Free-Cash-Flow 44.21
OMCL's Price-to-Free-Cash-Flow is ranked lower than
75% of the 677 Companies
in the Global Health Information Services industry.

( Industry Median: 24.32 vs. OMCL: 44.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
OMCL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.86  Med: 31.17 Max: 2576
Current: 44.21
7.86
2576
Price-to-Operating-Cash-Flow 30.49
OMCL's Price-to-Operating-Cash-Flow is ranked lower than
75% of the 856 Companies
in the Global Health Information Services industry.

( Industry Median: 17.68 vs. OMCL: 30.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OMCL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.85  Med: 20.63 Max: 841.67
Current: 30.49
6.85
841.67
EV-to-EBIT 263.62
OMCL's EV-to-EBIT is ranked lower than
97% of the 1770 Companies
in the Global Health Information Services industry.

( Industry Median: 17.68 vs. OMCL: 263.62 )
Ranked among companies with meaningful EV-to-EBIT only.
OMCL' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.7  Med: 24.8 Max: 262
Current: 263.62
5.7
262
EV-to-EBITDA 26.35
OMCL's EV-to-EBITDA is ranked lower than
75% of the 1910 Companies
in the Global Health Information Services industry.

( Industry Median: 13.76 vs. OMCL: 26.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMCL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 15.3 Max: 46.1
Current: 26.35
4
46.1
PEG Ratio 99.75
OMCL's PEG Ratio is ranked lower than
98% of the 567 Companies
in the Global Health Information Services industry.

( Industry Median: 1.98 vs. OMCL: 99.75 )
Ranked among companies with meaningful PEG Ratio only.
OMCL' s PEG Ratio Range Over the Past 10 Years
Min: 0.4  Med: 2.1 Max: 94.71
Current: 99.75
0.4
94.71
Shiller PE Ratio 74.88
OMCL's Shiller PE Ratio is ranked lower than
79% of the 291 Companies
in the Global Health Information Services industry.

( Industry Median: 38.24 vs. OMCL: 74.88 )
Ranked among companies with meaningful Shiller PE Ratio only.
OMCL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 36.8  Med: 55.29 Max: 75.28
Current: 74.88
36.8
75.28
Current Ratio 1.74
OMCL's Current Ratio is ranked lower than
56% of the 1750 Companies
in the Global Health Information Services industry.

( Industry Median: 1.94 vs. OMCL: 1.74 )
Ranked among companies with meaningful Current Ratio only.
OMCL' s Current Ratio Range Over the Past 10 Years
Min: 0.73  Med: 2.39 Max: 4.68
Current: 1.74
0.73
4.68
Quick Ratio 1.36
OMCL's Quick Ratio is ranked lower than
64% of the 1750 Companies
in the Global Health Information Services industry.

( Industry Median: 1.79 vs. OMCL: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
OMCL' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2 Max: 4.38
Current: 1.36
0.52
4.38
Days Inventory 64.68
OMCL's Days Inventory is ranked lower than
78% of the 1086 Companies
in the Global Health Information Services industry.

( Industry Median: 18.20 vs. OMCL: 64.68 )
Ranked among companies with meaningful Days Inventory only.
OMCL' s Days Inventory Range Over the Past 10 Years
Min: 35.43  Med: 54.71 Max: 60.27
Current: 64.68
35.43
60.27
Days Sales Outstanding 79.21
OMCL's Days Sales Outstanding is ranked lower than
59% of the 1492 Companies
in the Global Health Information Services industry.

( Industry Median: 68.98 vs. OMCL: 79.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMCL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.2  Med: 69.17 Max: 84.02
Current: 79.21
56.2
84.02
Days Payable 26.08
OMCL's Days Payable is ranked lower than
69% of the 1330 Companies
in the Global Health Information Services industry.

( Industry Median: 43.37 vs. OMCL: 26.08 )
Ranked among companies with meaningful Days Payable only.
OMCL' s Days Payable Range Over the Past 10 Years
Min: 26.08  Med: 34.86 Max: 46.45
Current: 26.08
26.08
46.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.40
OMCL's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 1148 Companies
in the Global Health Information Services industry.

( Industry Median: -2.60 vs. OMCL: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMCL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.8  Med: -3.3 Max: 1.6
Current: -1.4
-140.8
1.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.80
OMCL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
55% of the 771 Companies
in the Global Health Information Services industry.

( Industry Median: 1.97 vs. OMCL: 1.80 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OMCL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.08  Med: 1.52 Max: 8.59
Current: 1.8
1.08
8.59
Price-to-Median-PS-Value 0.98
OMCL's Price-to-Median-PS-Value is ranked higher than
65% of the 1498 Companies
in the Global Health Information Services industry.

( Industry Median: 1.15 vs. OMCL: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMCL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.09 Max: 1.96
Current: 0.98
0.23
1.96
Price-to-Peter-Lynch-Fair-Value 93.26
OMCL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
100% of the 339 Companies
in the Global Health Information Services industry.

( Industry Median: 1.60 vs. OMCL: 93.26 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
OMCL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.32  Med: 1.92 Max: 78.84
Current: 93.26
1.32
78.84
Earnings Yield (Greenblatt) % 0.38
OMCL's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 2521 Companies
in the Global Health Information Services industry.

( Industry Median: 3.23 vs. OMCL: 0.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMCL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 4 Max: 17.7
Current: 0.38
0.4
17.7
Forward Rate of Return (Yacktman) % 23.93
OMCL's Forward Rate of Return (Yacktman) % is ranked higher than
80% of the 773 Companies
in the Global Health Information Services industry.

( Industry Median: 10.33 vs. OMCL: 23.93 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
OMCL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.6  Med: 26.6 Max: 43.8
Current: 23.93
-2.6
43.8

More Statistics

Revenue (TTM) (Mil) $692.6
EPS (TTM) $ 0.02
Beta0.92
Short Percentage of Float13.36%
52-Week Range $28.74 - 41.15
Shares Outstanding (Mil)37.12

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 745 824
EPS ($) 1.34 2.19
EPS without NRI ($) 1.34 2.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OMCL

Headlines

Articles On GuruFocus.com
Omnicell Acquires InPharmics Apr 19 2017 
Omnicell Medication Adherence Named a 50+ Innovation Leader Apr 12 2017 
Ken Fisher's Top 5 New Portfolio Stocks Jul 27 2014 
Omnicell Inc. (OMCL) V.P., Finance & CFO Robin Gene Seim sells 1,250 Shares Feb 03 2011 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 11,997 Shares Jan 24 2011 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 11,997 Shares Jan 12 2011 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 937 Shares Jan 05 2011 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 3,351 Shares Dec 22 2010 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 1,500 Shares Dec 03 2010 
Omnicell Inc. (OMCL) V.P., Finance & CFO Robin Gene Seim sells 4,265 Shares Nov 30 2010 

More From Other Websites
Omnicell Acquires InPharmics Apr 19 2017
Omnicell Medication Adherence Named a 50+ Innovation Leader Apr 12 2017
Omnicell's Aesynt Buyout Looks Promising amid Several Woes Apr 07 2017
Omnicell's Newest Automated Dispensing Solutions to Be Showcased at the European Association of... Mar 22 2017
Why Is Omnicell (OMCL) Up 3% Since the Last Earnings Report? Mar 21 2017
Omnicell Supports Pharmacy Advancement through Unrestricted Grant Mar 20 2017
RBC Says These Top Health Care Stocks Could Be 2017 Takeover Candidates Mar 02 2017
Post Earnings Coverage as WebMD Net Income Surged 32%; Revenue Gained 8% Mar 02 2017
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise Feb 24 2017
Omnicell, Inc. :OMCL-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017
Inova Partners with Omnicell to Enhance Pharmacy Supply Chain Strategy Feb 21 2017
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss Feb 16 2017
Edited Transcript of OMCL earnings conference call or presentation 15-Feb-17 9:30pm GMT Feb 15 2017
Omnicell misses Street 4Q forecasts Feb 15 2017
Omnicell Reports Results for Fiscal Year and Fourth Quarter 2016 Feb 15 2017
Omnicell Partners with DCH Health for Sterile Compounding Feb 14 2017
Omnicell Launches Innovative Medication Adherence Automated Pharmacy Solution to Increase Pharmacy... Feb 14 2017
Omnicell Medication Management Solutions and Interoperability Featured at HIMSS17 with Real World... Feb 13 2017
DCH Health System Partners with Omnicell to Automate Sterile Compounding with Robotic IV Insourcing... Feb 13 2017
Omnicell to Release Fourth Quarter 2016 Earnings Results on February 15th Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)